US FDA Biomarker Qualification Process Improving, But Workload Remains An Issue

 
• By Grace Moser
  
The FDA qualified BMD as a surrogate endpoint for osteoporosis in December 2025. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from United States